GT Metabolic Solutions 

  Venture Capital  


  GT Metabolic Solutions  

The law normally requires people who offer financial products to give information to investors before they invest. This information is designed to help investors make an informed decision.

If you are an accredited investor under the definition of that term in Rule 501(a) of Regulation D of the USSecurities Act of 1933, the usual rules do not apply to offers of financial products made to you. As a result, you may not receive a complete and balanced set of information.

You will also have fewer other legal protections for these investments. Ask questions, read all documents carefully, and seek independent financial advice before committing yourself.


The Opportunity exists for Wholesalel investors to express interest in GT Metabolic Solutions (GT). 


Obesity is a Global epidemic, one of the leading factors for premature death in the developed world. In the USA, an estimated 42% of adults were obese in 2017 and linear time trend forecasts suggest that by 2030, 51% of the American population will be obese.  It is a health crisis which is linked with over forty other diseases including Diabetes, Heart disease, Stroke and Cancer which puts incredible pressure and cost on health systems. However Obesity is treatable and manageable. Bariatric Surgery removes a part of the stomach reducing food consumption and helping weight loss. The surgery is proven to work and deliver durable results but the market needs additional technologies to evolve, too few options exist for the surgeon and patients are stuck.

GT Metabolic Solutions The company develops technology which enables a new portfolio of procedures that will complement and expand the market by adapting the procedure to be less invasive, more efficient and less expensive. GT has a team of award winning industry leaders, that is experienced in the development and management of medical technologies and includes entrepreneurs and medical professionals. The size of the market is estimated at USD 3billion.

GT Metabolic Solutions is looking to raise USD15 million, raised funds will be used to take the company through initial Clinical Trials to a commercialization approval.

For more information you can access the investor deck by clicking the Documents tab.

You can also be connected with the US based advisors by clicking the register Interest button.

Issue Type:
Venture Capital
Health Care
isEOI: true

Investment Details

Investment Type: Wholesale

Wholesale Investment Type: NZ Wholesale Equities

Transaction Size:USD 25,000,000.00

Committed Capital: 

Pre-money valuation: 

Minimum Capital Raise: 

Share Price:USD 1.00

Unit Price:USD 1.00

Minimum Investment Size:USD 50,000.00

Document Name Description Date Uploaded
GT Pitchdeck CEROS_LB 21 March 2022 Preview/Download
Zoom: 0

You do not have any investments to report on.

No trade history available for this issue.

Secondary Market - GT Metabolic Solutions Wholesale

No secondary market listings for this issue availble at this time. Check the Exchange for more listings.